Compare Illumina, Inc. (ILMN) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nerdwallet Inc — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Nerdwallet Inc trades at $8.93 (market cap $603.70M). The key difference: Illumina, Inc. is far larger — about 46.3× Nerdwallet Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | NRDS | |
|---|---|---|
Market Cap | $27.94B | $603.70M |
Sector | Health | Financials |
52-Week High | $194.33 | $15.93 |
52-Week Low | $91.00 | $7.58 |
Enterprise Value | $29.33B | $518.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
NerdWallet (NRDS) trades at $9.17, down 0.97% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected. Revenue grew to $836.6M in 2025 with improving net margins from -1.9% in 2022 to 5.82%. Valuation metrics appear attractive with P/E of 9.96 and P/S of 0.81. Recent news highlights the company's pivot to higher-margin transactions and launch of financial resilience indices.
The stock presents a compelling value opportunity with 39% upside to the $12.75 consensus target. Strong profitability metrics (93% gross margin, 19.47% ROE) and positive cash flow trends support the bullish case. Key risks include search-driven revenue headwinds and competitive pressures in financial guidance markets. Analyst consensus leans bullish with 4 buy ratings versus 1 hold and 1 sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
